Carregant...
Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension
OBJECTIVES: To evaluate the effect of intrathecally (IT) delivered rituximab as a therapeutic intervention for progressive multiple sclerosis (PMS) during a 3-year follow-up period. METHODS: Participants of a 1-year open-label phase 1b study of IT delivered rituximab to patients with PMS were offere...
Guardat en:
| Publicat a: | J Neurol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Berlin Heidelberg
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7880973/ https://ncbi.nlm.nih.gov/pubmed/32901316 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00415-020-10210-0 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|